Literature DB >> 1646238

In situ evidence for HPV 16, 18, 33 integration in cervical squamous cell cancer in Britain and South Africa.

K Cooper1, C S Herrington, A K Graham, M F Evans, J O McGee.   

Abstract

In a previous study three types of HPV signal were described in CIN. It was suggested that a type 1 signal represented episomal HPV while a type 2 signal represented integrated HPV; and a type 3 signal was indicative of both episomal and integrated HPV. To test this hypothesis 91 squamous cell cancers (SCC) of the cervix from Britain and South Africa were examined for HPV 6, 11, 16, 18, 31, 33, 35. Of the South African group (n = 69) 64% contained HPV types 16 (n = 29) and 18 (n = 15). The SCC in the British group (n = 22) contained HPV 16 and HPV 33 in 12 and three cases, respectively. Of the HPV positive biopsy specimens, 86% showed a type 2 signal in keratinising and non-keratinising tumours and the remainder a type 3 signal. Type 3 signal was present only in keratinising tumours. The presence of punctate signal in 100% of HPV containing SCC, together with localisation of HPV signal to sister chromatids in tumour cell mitotic figures in vivo, provides further evidence for type 2, and the punctate component of type 3 signal representing viral integration.

Entities:  

Mesh:

Year:  1991        PMID: 1646238      PMCID: PMC496873          DOI: 10.1136/jcp.44.5.406

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  19 in total

Review 1.  The cell biology of human papillomavirus transformed cells.

Authors:  G Matlashewski
Journal:  Anticancer Res       Date:  1989 Sep-Oct       Impact factor: 2.480

Review 2.  Role of papillomaviruses.

Authors:  F Chang
Journal:  J Clin Pathol       Date:  1990-04       Impact factor: 3.411

3.  Chromosomal integration sites of human papillomavirus DNA in three cervical cancer cell lines mapped by in situ hybridization.

Authors:  A Mincheva; L Gissmann; H zur Hausen
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

4.  Multiple infections in cases of cervical cancer from a high-incidence area in tropical Africa.

Authors:  R Schmauz; P Okong; E M de Villiers; R Dennin; L Brade; S K Lwanga; R Owor
Journal:  Int J Cancer       Date:  1989-05-15       Impact factor: 7.396

5.  Prevalence of human papillomavirus type 16 DNA in cervical carcinoma samples in East Anglia.

Authors:  S M Scholl; E M Pillers; R E Robinson; P J Farrell
Journal:  Int J Cancer       Date:  1985-02-15       Impact factor: 7.396

6.  Demonstration of multiple HPV types in normal cervix and in cervical squamous cell carcinoma using the polymerase chain reaction on paraffin wax embedded material.

Authors:  N R Griffin; I S Bevan; F A Lewis; M Wells; L S Young
Journal:  J Clin Pathol       Date:  1990-01       Impact factor: 3.411

7.  In situ hybridization analysis of HPV DNA in cervical precancer and cervical cancers from China.

Authors:  H X Ji; S Syrjänen; K Syrjänen; A R Wu; F J Chang
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

8.  The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours.

Authors:  M Dürst; A Kleinheinz; M Hotz; L Gissmann
Journal:  J Gen Virol       Date:  1985-07       Impact factor: 3.891

9.  Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA.

Authors:  G Riou; M Favre; D Jeannel; J Bourhis; V Le Doussal; G Orth
Journal:  Lancet       Date:  1990-05-19       Impact factor: 79.321

10.  A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions.

Authors:  M Dürst; L Gissmann; H Ikenberg; H zur Hausen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

View more
  16 in total

Review 1.  Laboratory techniques in the investigation of human papillomavirus infection.

Authors:  E M de Villiers
Journal:  Genitourin Med       Date:  1992-02

Review 2.  Human papillomavirus, integration and cervical carcinogenesis: a clinicopathological perspective.

Authors:  K Cooper; J O McGee
Journal:  Mol Pathol       Date:  1997-02

3.  Episomal and integrated human papillomavirus in cervical neoplasia shown by non-isotopic in situ hybridisation.

Authors:  K Cooper; C S Herrington; J E Stickland; M F Evans; J O McGee
Journal:  J Clin Pathol       Date:  1991-12       Impact factor: 3.411

4.  Human papillomavirus and schistosomiasis associated bladder cancer.

Authors:  K Cooper; Z Haffajee; L Taylor
Journal:  Mol Pathol       Date:  1997-06

5.  Detection of human papillomavirus in large cell neuroendocrine carcinoma of the uterine cervix: a study of 12 cases.

Authors:  W Grayson; H A Rhemtula; L F Taylor; U Allard; A J Tiltman
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

6.  Role of human papillomavirus in determining the HLA associated risk of cervical carcinogenesis.

Authors:  W Z Mehal; Y M Lo; C S Herrington; M F Evans; M C Papadopoulos; K Odunis; T S Ganesan; J O McGee; J I Bell; K A Fleming
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

7.  Sequence variation in the L1 gene of human papillomavirus type 16 from Africa.

Authors:  J E Ramesar; E P Rybicki; A L Williamson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

Review 8.  Expression of p53 protein in laryngeal squamous cell carcinoma and dysplasia: possible correlation with human papillomavirus infection and clinicopathological findings.

Authors:  V Gorgoulis; G Rassidakis; A Karameris; A Giatromanolaki; C Barbatis; C Kittas
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  The discrimination of high-risk HPV types by in situ hybridization and the polymerase chain reaction.

Authors:  C S Herrington; S M Anderson; A K Graham; J O McGee
Journal:  Histochem J       Date:  1993-03

10.  Integration of human papillomavirus types 16 and 18 in cervical adenocarcinoma.

Authors:  K Cooper; C S Herrington; E S Lo; M F Evans; J O McGee
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.